Abstract
The present study was designed to explore the antioxidative status and circulating biochemical markers having a potential role in the pathogenesis of ethambutol (EMB) induced toxic optic neuropathy (TON) among diabetic and non-diabetic patients.
Fifty patients under complete therapy of EMB for tuberculosis were included in the present study. Inclusion criteria for patients were to receive EMB everyday during treatment, a dose of 25mg/kg for initial 2months and 15mg/kg during the rest of therapy period. We conducted color vision and visual acuity test for all patients.
Fifteen out of fifty EMB induced TON patients, were found to be diabetic. Color vision and visual acuity test results were evaluated for diabetic and non-diabetic as well as twenty age matched controls. The results demonstrated a significant pattern of circulating biochemical markers between the studied groups. Data regarding hematological (RBC, p value=0.02; Hemoglobin, p value=0.02), hepatic (total bilirubin, p value=0.01), renal (urea, p value=0.03; creatinine, p value=0.007), lipid (total cholesterol, p value=0.01; total triglycerides, p value=0.03) and antioxidative (superoxide dismutase, p value=0.005; glutathione, p value=0.02; catalase, p value=0.02) profile showed a highly significant difference among the studied groups specially patients with diabetes. Malondialdehyde (MDA) level had gone significantly up in diabetic TON patients (p value=0.02), in comparison to other antioxidants and vitamins (Vit). Vit-A, E, B1, B12 and Zinc seem to be playing a major role in the pathogenesis of TON, specially Vit-E and B1 surpassed all the antioxidants as having highly significant inverse relationships with MDA (MDA vs Vit-E, r=−0.676** and MDA vs Vit-B1, r=−0.724** respectively).
We conclude that during the ethambutol therapy the decreased levels of Vit-E and Vit-B1 possibly play a role in the development of TON and may be used as therapeutic agents to lessen the deleterious effects of ethambutol.